
    
      COPD patients on LABA/ICS maintenance therapy with dyspnea (mMRC ≥ 1) and other symptoms
      (CATTM ≥ 10), who are switched to either Spiolto® Respimat® in the new reusable inhaler or
      any triple therapy (LAMA + LABA + ICS) as an open or fixed combination according to approved
      SmPCs at baseline at the discretion of their attending physician.
    
  